Literature DB >> 18483241

Down-regulation of p57Kip2 induces prostate cancer in the mouse.

Ren Jie Jin1, Yongsoo Lho, Yongqing Wang, Mingfang Ao, Monica Patricia Revelo, Simon W Hayward, Marcia L Wills, Susan K Logan, Pumin Zhang, Robert J Matusik.   

Abstract

p57(Kip2) has been considered a candidate tumor suppressor gene because of its location in the genome, biochemical activities, and imprinting status. However, little is known about the role of p57(Kip2) in tumorigenesis and cancer progression. Here, we show that the expression of p57(Kip2) is significantly decreased in human prostate cancer, and the overexpression of p57(Kip2) in prostate cancer cells significantly suppressed cell proliferation and reduced invasive ability. In addition, overexpression of p57(Kip2) in LNCaP cells inhibited tumor formation in nude mice, resulting in well-differentiated squamous tumors rather than adenocarcinoma. Furthermore, the prostates of p57(Kip2) knockout mice developed prostatic intraepithelial neoplasia and adenocarcinoma. Remarkably, this mouse prostate cancer is pathologically identical to human prostate adenocarcinoma. Therefore, these results strongly suggest that p57(Kip2) is an important gene in prostate cancer tumorigenesis, and the p57(Kip2) pathway may be a potential target for prostate cancer prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483241     DOI: 10.1158/0008-5472.CAN-08-0073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors.

Authors:  Nawal Bendris; Bénédicte Lemmers; Jean Marie Blanchard
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Authors:  Joshua Z Press; Kaitlyn Wurz; Barbara M Norquist; Ming K Lee; Christopher Pennil; Rochelle Garcia; Piri Welcsh; Barbara A Goff; Elizabeth M Swisher
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

3.  Machine learning methods for prediction of CDK-inhibitors.

Authors:  Jayashree Ramana; Dinesh Gupta
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

4.  Deregulation of an imprinted gene network in prostate cancer.

Authors:  Teodora Ribarska; Wolfgang Goering; Johanna Droop; Klaus-Marius Bastian; Marc Ingenwerth; Wolfgang A Schulz
Journal:  Epigenetics       Date:  2014-02-10       Impact factor: 4.528

5.  Optimization based tumor classification from microarray gene expression data.

Authors:  Onur Dagliyan; Fadime Uney-Yuksektepe; I Halil Kavakli; Metin Turkay
Journal:  PLoS One       Date:  2011-02-04       Impact factor: 3.240

6.  Mouse models of prostate cancer.

Authors:  Kenneth C Valkenburg; Bart O Williams
Journal:  Prostate Cancer       Date:  2011-02-23

7.  p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect.

Authors:  E Kavanagh; P Vlachos; V Emourgeon; J Rodhe; B Joseph
Journal:  Cell Death Dis       Date:  2012-05-17       Impact factor: 8.469

8.  The role of cytoplasmic p57 in invasion of hepatocellular carcinoma.

Authors:  Hui Guo; Yi Li; Tao Tian; Lili Han; Zhiping Ruan; Xuan Liang; Wenjuan Wang; Kejun Nan
Journal:  BMC Gastroenterol       Date:  2015-08-15       Impact factor: 3.067

9.  RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas.

Authors:  Pilar López-Nieva; Pablo Fernández-Navarro; Concepción Vaquero-Lorenzo; María Villa-Morales; Osvaldo Graña-Castro; María Ángeles Cobos-Fernández; José Luis López-Lorenzo; Pilar Llamas; Laura González-Sanchez; Isabel Sastre; Marina Pollan; Marcos Malumbres; Javier Santos; José Fernández-Piqueras
Journal:  BMC Cancer       Date:  2018-04-16       Impact factor: 4.430

10.  MicroRNA-21 inhibits p57Kip2 expression in prostate cancer.

Authors:  Sweta Mishra; Chun-Lin Lin; Tim H-M Huang; Hakim Bouamar; Lu-Zhe Sun
Journal:  Mol Cancer       Date:  2014-09-12       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.